First-in-human clinical trial results with ABBV-184, a first-in-class T-cell receptor/anti-CD3 bispecific protein, in adults with previously treated AML or NSCLC.

Pierre PeterlinEsma Saada-BouzidMor MoskovitzArnaud PigneuxJunichiro YudaMahipal SinnollareddyWilliam R HennerDiana ChenKevin J FreiseRachel S LeibmanAbraham AvigdorToshio Shimizu

Published in: Expert review of anticancer therapy (2024)

NCT04272203.

Keyphrases

clinical trial
endothelial cells
small cell lung cancer
acute myeloid leukemia
binding protein
induced pluripotent stem cells
advanced non small cell lung cancer
protein protein
amino acid
randomized controlled trial
allogeneic hematopoietic stem cell transplantation
small molecule
nk cells
brain metastases